DDInter826 DDInter1055
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Glipizide {u} may lead to a major life threatening interaction when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glipizide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glipizide {u} may lead to a major life threatening interaction when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Glipizide {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Glipizide {u} may lead to a major life threatening interaction when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glipizide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glipizide {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glipizide {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Glipizide may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Glipizide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Glipizide may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levofloxacin (Compound)
Glipizide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Levofloxacin (Compound)
Glipizide may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Glipizide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Glipizide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Glipizide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)